Tirzepatide (Mounjaro), a dual GLP-1/GIP receptor agonist, received UK approval for type 2 diabetes and is under evaluation for obesity treatment
Bring a detailed record that includes: Pre-existing conditions such as diabetes, hypertension, PCOS Family medical history detailing obesity, metabolic disorders, and endocrine conditions Current medications including prescriptions, supplements, and over-the-counter drugs Previous surgeries or procedures, particularly those related to weight loss or digestion (e.g., bariatric surgery) Before your visit, familiarize yourself with GLP-1 medications like Wegovy, Ozempic, Zepbound, and Mounjaro
Chronic intermittent hypoxia in obstructive sleep apnea: a narrative R Eview from pathophysiological pathways to a precision clinical approach
Placellas extensive expertise and meticulous approaches ensure you receive expert weight loss care throughout your journey